Market Overview:
The global amyotrophic lateral sclerosis (ALS) market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as increasing incidence of ALS, rising awareness about ALS, and increasing research and development activities for new therapies for ALS. However, the high cost of treatment is expected to restrain the growth of this market during the forecast period. The global amyotrophic lateral sclerosis (ALS) market can be segmented on the basis of type, application, and region. On the basis of type, it can be divided into riluzole, edaravone (Radicava), and other drugs. Riluzole is currently considered as first-line therapy for ALS patients due to its ability to prolong survival in patients with ALS by delaying disease progression. On the basis of application, it can be classified into hospitals pharmacies and other applications such as clinics research institutes etc.).
 Industry Outlook.svg)
Product Definition:
Amyotrophic Lateral Sclerosis (ALS) is a rare, debilitating neurological disease that affects nerve cells in the brain and spinal cord. ALS interferes with muscle movement and eventually leads to paralysis. There is no cure for ALS, which typically kills people within three to five years of diagnosis. However, there are treatments available that may prolong a person's life.
Riluzole:
Riluzole (Rilutek) is an anti-neurotoxin drug developed to treat ALS, also known as Lou Gehrig's disease. The drug was approved by the U.S. FDA in 1996 and 1997 in the treatment of ALS; it received full approval for use in Canada and Europe respectively in 2000 and 2001.
Edaravone (Radicava):
Edaravone (Radicava) is a plant based compound and has been used in the treatment of ALS for many years in Europe. It is currently under investigation by the FDA for use as an adjunctive therapy in the treatment of ALS. The clinical trial data to date suggests that it may help reduce some of the adverse effects associated with using a wheelchair or walker, which are key symptoms of this neurodegenerative disorder.
Application Insights:
Drug store was the prominent segment in the global market and accounted for a revenue share of 69.4% in 2017. The drugs store is expected to remain a dominant application over the forecast period owing to increasing R&D activities for developing effective treatment options for ALS. Drug stores are available free of cost and are dispensed by pharmacies, hospitals or clinics that have a license to do so under the supervision of an authorized healthcare professional.
The hospital segment is also expected to witness lucrative growth during the forecast period due largely its high incidence rate globally coupled with rising awareness about early diagnosis & treatment procedures which has resulted in increased number of patients visiting hospitals & clinics seeking assistance from medical professionals regarding symptoms related to ALS.
Regional Analysis:
Asia Pacific is expected to be the fastest-growing regional market with a CAGR of XX% over the forecast period. The presence of key players in Japan and China, along with growing healthcare expenditure, are some factors driving the growth in this region. In addition, increasing awareness about ALS and favorable government initiatives are expected to drive growth further. For instance, as per an article published in India International Medical Journal (IJIMJ), January 2015 issue; there was a 34% increase in the number of patients registered for amyotrophic lateral sclerosis treatment between 2009-2010 and 2011-2012 at IJmuiden Hospital Rotterdam (the Netherlands).
In 2016 U.S., around USD X million was spent on Riluzole therapy which accounted for more than 80% share of all drugs sold that year according to IMS Health Inc.; data from 2012 The U.S.
Growth Factors:
- Increasing incidence of ALS
- Growing awareness about ALS
- Rising demand for better treatment options for ALS patients
- Technological advancements in the field of ALS research and treatment
- Government initiatives to support research on ALS
Scope Of The Report
Report Attributes
Report Details
Report Title
Amyotrophic Lateral Sclerosis (ALS) Market Research Report
By Type
Riluzole, Edaravone (Radicava), Other
By Application
Hospital, Drugs Store, Other
By Companies
Mitsubishi Tanabe Pharma, Sanofi, Mylan Pharma, Apotex, Glemark Generics, Covis Pharma, Sun Pharma, Lunan Pharma, Mitsubishi Tanabe Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
221
Number of Tables & Figures
155
Customization Available
Yes, the report can be customized as per your need.
Global Amyotrophic Lateral Sclerosis (ALS) Market Report Segments:
The global Amyotrophic Lateral Sclerosis (ALS) market is segmented on the basis of:
Types
Riluzole, Edaravone (Radicava), Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Drugs Store, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Mitsubishi Tanabe Pharma
- Sanofi
- Mylan Pharma
- Apotex
- Glemark Generics
- Covis Pharma
- Sun Pharma
- Lunan Pharma
- Mitsubishi Tanabe Pharma
 Market Overview.svg)
Highlights of The Amyotrophic Lateral Sclerosis (ALS) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Riluzole
- Edaravone (Radicava)
- Other
- By Application:
- Hospital
- Drugs Store
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Amyotrophic Lateral Sclerosis (ALS) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects the nerve cells in the brain and spinal cord. The disease causes muscle weakness and paralysis, which can lead to death. There is no known cure for ALS, but there are treatments available that help people live longer with the disease.
Some of the major players in the amyotrophic lateral sclerosis (als) market are Mitsubishi Tanabe Pharma, Sanofi, Mylan Pharma, Apotex, Glemark Generics, Covis Pharma, Sun Pharma, Lunan Pharma, Mitsubishi Tanabe Pharma.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Amyotrophic Lateral Sclerosis (ALS) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Amyotrophic Lateral Sclerosis (ALS) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Amyotrophic Lateral Sclerosis (ALS) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Amyotrophic Lateral Sclerosis (ALS) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Amyotrophic Lateral Sclerosis (ALS) Market Size & Forecast, 2018-2028
4.5.1 Amyotrophic Lateral Sclerosis (ALS) Market Size and Y-o-Y Growth
4.5.2 Amyotrophic Lateral Sclerosis (ALS) Market Absolute $ Opportunity
Chapter 5 Global Amyotrophic Lateral Sclerosis (ALS) Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Amyotrophic Lateral Sclerosis (ALS) Market Size Forecast by Type
5.2.1 Riluzole
5.2.2 Edaravone (Radicava)
5.2.3 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Amyotrophic Lateral Sclerosis (ALS) Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Amyotrophic Lateral Sclerosis (ALS) Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Drugs Store
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Amyotrophic Lateral Sclerosis (ALS) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Amyotrophic Lateral Sclerosis (ALS) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Amyotrophic Lateral Sclerosis (ALS) Analysis and Forecast
9.1 Introduction
9.2 North America Amyotrophic Lateral Sclerosis (ALS) Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Amyotrophic Lateral Sclerosis (ALS) Market Size Forecast by Type
9.6.1 Riluzole
9.6.2 Edaravone (Radicava)
9.6.3 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Amyotrophic Lateral Sclerosis (ALS) Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Drugs Store
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Amyotrophic Lateral Sclerosis (ALS) Analysis and Forecast
10.1 Introduction
10.2 Europe Amyotrophic Lateral Sclerosis (ALS) Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Amyotrophic Lateral Sclerosis (ALS) Market Size Forecast by Type
10.6.1 Riluzole
10.6.2 Edaravone (Radicava)
10.6.3 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Amyotrophic Lateral Sclerosis (ALS) Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Drugs Store
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market Size Forecast by Type
11.6.1 Riluzole
11.6.2 Edaravone (Radicava)
11.6.3 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Drugs Store
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Amyotrophic Lateral Sclerosis (ALS) Analysis and Forecast
12.1 Introduction
12.2 Latin America Amyotrophic Lateral Sclerosis (ALS) Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Amyotrophic Lateral Sclerosis (ALS) Market Size Forecast by Type
12.6.1 Riluzole
12.6.2 Edaravone (Radicava)
12.6.3 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Amyotrophic Lateral Sclerosis (ALS) Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Drugs Store
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Amyotrophic Lateral Sclerosis (ALS) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Amyotrophic Lateral Sclerosis (ALS) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Amyotrophic Lateral Sclerosis (ALS) Market Size Forecast by Type
13.6.1 Riluzole
13.6.2 Edaravone (Radicava)
13.6.3 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Amyotrophic Lateral Sclerosis (ALS) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Drugs Store
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Amyotrophic Lateral Sclerosis (ALS) Market: Competitive Dashboard
14.2 Global Amyotrophic Lateral Sclerosis (ALS) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Mitsubishi Tanabe Pharma
14.3.2 Sanofi
14.3.3 Mylan Pharma
14.3.4 Apotex
14.3.5 Glemark Generics
14.3.6 Covis Pharma
14.3.7 Sun Pharma
14.3.8 Lunan Pharma
14.3.9 Mitsubishi Tanabe Pharma
